Use of mogamulizumab in cutaneous T-cell lymphomas among people living with HIV: insights from a nationwide French cohort

Résumé fourni par la source

We report the first nationwide French cohort of people living with HIV treated with mogamulizumab for cutaneous T-cell lymphomas. Mogamulizumab demonstrated sustained efficacy and good tolerability, including in a patient treated continuously for over 3 years, with no opportunistic infections or HIV reactivation. Beyond clinical outcomes, our findings highlight the dual role of CCR4 in HIV persistence and immune regulation, warranting cardiovascular monitoring in this population.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.